AP NEWS

M3 Biotechnology Names Deborah C. Hopkins to Business and Strategy Advisory Board

July 10, 2018

SEATTLE--(BUSINESS WIRE)--Jul 10, 2018--M3 Biotechnology, a clinical therapeutics company developing novel regenerative disease-modifying therapies for Alzheimer’s and other neurodegenerative diseases, announced today that Deborah (Debby) C. Hopkins has been elected to the Company’s Business and Strategy Advisory Board effective July 10, 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180710005041/en/

Ms. Hopkins is an Independent Board Member and active advisor to many early-stage companies. Her C suite experiences in finance, technology and innovation across multiple industries provides a unique view to support management teams in pursuit of growth.

“We are excited to attract such an experienced and respected leader to help advise us as we continue to grow our company,” said Leen Kawas, CEO and President of M3 Biotechnology. “Debby has had significant executive leadership roles at Citi, The Boeing Company, General Motors, and Lucent Technologies. Her background and diverse industry experience make her an invaluable addition to the M3 Team.”

Debby said, “Neurodegenerative diseases are one of the most pressing issues in our health care system. It has affected my family as it has many others. I am honored to be a part of the growth of M3 Bio as it works to bring innovative solutions to market to mitigate these quality of life challenges.”

She is a member of the Board of Directors at Union Pacific and Marsh & McLennan. Debby is an Advisory Board Member at Marto Capital, and Sales Hero, and an Executive Fellow at UC Berkeley’s Haas School of Business. She is a Board Member at St. John’s Hospital Foundation and a Trustee for Silicon Couloir, both located in Jackson WY.

Debby was founder and CEO of Citi Ventures based in Silicon Valley, and Citi’s first Chief Innovation Officer. She and her team introduced a systematic process to respond to the digital disruption engendered by the many new competitors and technologies emerging in financial services. This included a robust venture investing program, sponsorship of a global network of labs, and the implementation of a growth operating system across the enterprise named D10X.

Debby served on the Boards of DuPont, Dendrite and Qlik Technologies. Fortune twice placed Debby in the top 10 most powerful women in business and she was on the Institutional Investor’s Top 50 list every year from 2011 until her retirement. Debby holds honorary doctorate degrees from Westminster College and Walsh College.

About M3 Biotechnology, Inc.

M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. For more information, visit www.m3bio.com.

M3 Biotechnology is conducting first-in-human Phase I clinical trials for their Alzheimer’s therapy that is expected to slow or stop disease progression as indicated by pre-clinical studies. For information about the trials, please visit www.clinicaltrials.gov. To inquire about participation, please contact Biotrial at (844) 246-8459 or recruitment@biotrial.com and specify the M3 Biotechnology Alzheimer’s study.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005041/en/

CONTACT: M3 Biotechnology, Inc.

Media Contact:

Josh Pan

info@m3bio.com

KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: M3 Biotechnology, Inc.

Copyright Business Wire 2018.

PUB: 07/10/2018 07:00 AM/DISC: 07/10/2018 07:01 AM

http://www.businesswire.com/news/home/20180710005041/en

AP RADIO
Update hourly